| Recruiting | Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer NCT07484022 | Generate Biomedicines | Phase 1 |
| Recruiting | Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma NCT07492628 | Beijing Biotech | Phase 1 |
| Withdrawn | N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer NCT07217496 | Vadim S Koshkin | Phase 1 |
| Not Yet Recruiting | A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer NCT07386847 | Pfizer | — |
| Recruiting | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial C NCT07221942 | Fox Chase Cancer Center | Phase 2 |
| Recruiting | A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma NCT07390617 | Memorial Sloan Kettering Cancer Center | — |
| Recruiting | A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Tr NCT06524544 | National Cancer Institute (NCI) | Phase 3 |
| Recruiting | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer NCT06862219 | Astellas Pharma Global Development, Inc. | Phase 4 |
| Recruiting | Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite NCT06439836 | National Cancer Institute (NCI) | Phase 1 |
| Recruiting | Criteria for Selecting First-line Metastatic Treatment for Patients With Urothelial Carcinoma NCT07339878 | University Hospital, Strasbourg, France | — |
| Recruiting | Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors NCT06493552 | Vasgene Therapeutics, Inc | Phase 2 / Phase 3 |
| Active Not Recruiting | A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and With NCT06483334 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Recruiting | Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected NCT06265285 | Mayo Clinic | Phase 2 |
| Withdrawn | Study of OB-002 in Patients With Refractory Metastatic Cancer NCT05940844 | Orion Biotechnology Polska Sp. z o.o. | Phase 1 |
| Withdrawn | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer. NCT06018116 | CHU de Quebec-Universite Laval | Phase 2 |
| Withdrawn | A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA) NCT06050954 | Fox Chase Cancer Center | Phase 2 |
| Active Not Recruiting | A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in Fir NCT05845814 | Merck Sharp & Dohme LLC | Phase 1 / Phase 2 |
| Active Not Recruiting | Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma NCT05923190 | Fox Chase Cancer Center | Phase 2 |
| Unknown | Utidelone Treated for the Recurrent or Metastatic Urothelial Carcinoma NCT05895864 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Recruiting | CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Pati NCT05733000 | Northwestern University | Phase 2 |
| Terminated | Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer NCT04936230 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors NCT05544552 | Tyra Biosciences, Inc | Phase 1 / Phase 2 |
| Completed | SOGUG-AVELUMAB_RWD NCT05700344 | Spanish Oncology Genito-Urinary Group | — |
| Active Not Recruiting | Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemo NCT04963153 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy NCT04637594 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Recruiting | Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Soli NCT05269381 | Mayo Clinic | Phase 1 / Phase 2 |
| Active Not Recruiting | Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma NCT05154994 | University of Utah | Phase 1 |
| Active Not Recruiting | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced NCT04514484 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib NCT05052372 | xCures | — |
| Recruiting | A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674 | Nurix Therapeutics, Inc. | Phase 1 |
| Active Not Recruiting | ARID1A and/or KDM6A Mutation and CXCL13 Expression NCT04953104 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer NCT04878029 | Emory University | Phase 1 |
| Terminated | Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab NCT04639245 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastat NCT04579224 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Cryoablation With Pembrolizumab Or Avelumab In Urothelial Carcinoma NCT04701918 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma NCT04848519 | Emory University | Phase 2 |
| Recruiting | Sacituzumab Govitecan Plus EV in Metastatic UC NCT04724018 | Dana-Farber Cancer Institute | Phase 1 / Phase 2 |
| Active Not Recruiting | Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Pat NCT04863885 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 / Phase 2 |
| Unknown | A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Can NCT04839510 | Shanghai Miracogen Inc. | Phase 2 |
| Terminated | Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced NCT04856189 | Mamta Parikh | Phase 1 / Phase 2 |
| Recruiting | Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, t NCT04693377 | M.D. Anderson Cancer Center | N/A |
| Active Not Recruiting | A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing NCT06129084 | Bernie Eigl | — |
| Recruiting | Urine Omics Predicting IO Therapy Responses in mUC Patients NCT04641936 | National Taiwan University Hospital | — |
| Active Not Recruiting | DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers NCT04388852 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma NCT04486781 | Vasgene Therapeutics, Inc | Phase 2 |
| Terminated | Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) NCT04003610 | Incyte Corporation | Phase 2 |
| Unknown | A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, NCT04383067 | Sheba Medical Center | Phase 2 |
| Active Not Recruiting | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors NCT04007744 | Mayo Clinic | Phase 1 |
| Completed | A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Adva NCT04200963 | Ikena Oncology | Phase 1 |
| Active Not Recruiting | Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelia NCT03854474 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Recruiting | An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Bi NCT04623502 | University of Texas Southwestern Medical Center | N/A |
| Completed | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial C NCT03513952 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer NCT03744793 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors NCT03682289 | Rahul Aggarwal | Phase 2 |
| Completed | Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma NCT03464734 | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Phase 2 |
| Completed | Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma NCT03534804 | University of Utah | Phase 2 |
| Completed | Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies NCT03590054 | Rahul Aggarwal | Phase 1 |
| Terminated | Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma NCT03397394 | pharmaand GmbH | Phase 2 |
| Completed | INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers NCT03071328 | Duke University | EARLY_Phase 1 |
| Active Not Recruiting | Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mut NCT03047213 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer NCT02693717 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers NCT03115801 | Weill Medical College of Cornell University | Phase 2 |
| Active Not Recruiting | Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothe NCT02420847 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder C NCT02351739 | Acerta Pharma BV | Phase 2 |
| Active Not Recruiting | Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With NCT01552434 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary NCT00942331 | National Cancer Institute (NCI) | Phase 3 |
| Active Not Recruiting | Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney NCT00365157 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |